Research & Development

Gilead, Tango to partner on targeted immuno-oncology therapies

Gilead Sciences and Tango Therapeutics have entered into a global collaboration to discover, develop and commercialize a pipeline of targeted immuno-oncology treatments for cancer.

Terns raises $80m to advance drug pipeline for NASH and cancer treatment

Terns Pharmaceuticals, a biopharma company focused on discovering and developing molecularly targeted, oral, small-molecule drugs for the treatment of NASH and cancer, has raised $80m through a Series B financing round.

Lilly, Dicerna to collaborate on RNAi research for several targets

Eli Lilly and Company (Lilly) and Dicerna Pharmaceuticals have signed a global licensing and research collaboration focused on the discovery, development and commercialization of new drugs in the areas of cardio-metabolic disease, neurodegeneration and pain.

Alexion, Dicerna to discover RNAi Therapies for complement-mediated diseases

Alexion Pharmaceuticals and Dicerna Pharmaceuticals have entered into a collaboration to discover and develop RNA interference (RNAi) therapies for complement-mediated diseases.

Biotechnology firm Stoke Therapeutics raises $90m financing

Stoke Therapeutics, a US-based biotechnology company focused on the development of drugs for severe genetic diseases, has raised $90m in a Series B financing round.

Bain Capital, Pfizer create new CNS company Cerevel Therapeutics

Private equity firm Bain Capital has joined forces with US pharma giant Pfizer to create a new biopharmaceutical company, dubbed Cerevel Therapeutics, which will focus on developing drugs for the treatment of central nervous system (CNS) disorders.

CANbridge, WuXi Biologics collaborate on rare disease therapeutics

China-based biopharmaceutical firm CANbridge Pharmaceutical and global open-access biologics technology platform company WuXi Biologics have entered into a partnership for rare disease therapeutics.

FSD Pharma signs binding LOI to buy Therapix Biosciences

FSD Pharma has signed a binding letter of intent (LOI) to acquire Therapix Biosciences, a NASDAQ traded pharmaceutical company focused on the development of Cannabinoid-based treatments.

Oncology startup TP Therapeutics raises $80m in financing

TP Therapeutics, a San Diego-based clinical-stage precision oncology company, has raised $80m in a new funding round led by Foresite Capital and venBio Partners.